PURPOSE: Although the life expectancy of patients with follicular lymphoma (FL) has increased, little is known of their causes of death (CODs) in the rituximab era. PATIENTS AND METHODS: We pooled two cohorts of newly diagnosed patients with FL grade 1-3A. Patients were enrolled between 2001 and 2013 in two French referral institutions (N = 734; median follow-up 89 months) and 2002 and 2012 in the University of Iowa and Mayo Clinic Specialized Program of Research Excellence (SPORE; N = 920; median follow-up 84 months). COD was classified as being a result of lymphoma, other malignancy, treatment related, or all other causes. RESULTS: Ten-year overall survival was comparable in the French (80%) and US (77%) cohorts. We were able to classify COD in 248 (88%) of 283 decedents. In the overall cohort, lymphoma was the most common COD, with a cumulative incidence of 10.3% at 10 years, followed by treatment-related mortality (3.0%), other malignancy (2.9%), other causes (2.2%), and unknown (3.0%). The 10-year cumulative incidence of death as a result of lymphoma or treatment was higher than death as a result of all other causes for each age group (including patients ≥ 70 years of age at diagnosis [25.4% v 16.6%]) Follicular Lymphoma International Prognostic Index score 3 to 5 (27.4% v 5.2%), but not Follicular Lymphoma International Prognostic Index score 0 to 1 (4.0% v 3.7%); for patients who failed to achieve event-free survival within 24 months from diagnosis (36.1% v 7.0%), but not for patients who achieved event-free survival within 24 months of diagnosis (6.7% v 5.7%); and for patients with a history of transformed FL (45.9% v 4.7%), but not among patients without (8.1% v 6.2%). Overall, 77 of 140 deaths as a result of lymphoma occurred in patients whose FL transformed after diagnosis. CONCLUSION: Despite the improvement in overall survival in patients with FL in the rituximab era, their leading COD remains lymphoma, especially after disease transformation. Treatment-related mortality also represents a concern, which supports the need for less-toxic therapies.
PURPOSE: Although the life expectancy of patients with follicular lymphoma (FL) has increased, little is known of their causes of death (CODs) in the rituximab era. PATIENTS AND METHODS: We pooled two cohorts of newly diagnosed patients with FL grade 1-3A. Patients were enrolled between 2001 and 2013 in two French referral institutions (N = 734; median follow-up 89 months) and 2002 and 2012 in the University of Iowa and Mayo Clinic Specialized Program of Research Excellence (SPORE; N = 920; median follow-up 84 months). COD was classified as being a result of lymphoma, other malignancy, treatment related, or all other causes. RESULTS: Ten-year overall survival was comparable in the French (80%) and US (77%) cohorts. We were able to classify COD in 248 (88%) of 283 decedents. In the overall cohort, lymphoma was the most common COD, with a cumulative incidence of 10.3% at 10 years, followed by treatment-related mortality (3.0%), other malignancy (2.9%), other causes (2.2%), and unknown (3.0%). The 10-year cumulative incidence of death as a result of lymphoma or treatment was higher than death as a result of all other causes for each age group (including patients ≥ 70 years of age at diagnosis [25.4% v 16.6%]) Follicular Lymphoma International Prognostic Index score 3 to 5 (27.4% v 5.2%), but not Follicular Lymphoma International Prognostic Index score 0 to 1 (4.0% v 3.7%); for patients who failed to achieve event-free survival within 24 months from diagnosis (36.1% v 7.0%), but not for patients who achieved event-free survival within 24 months of diagnosis (6.7% v 5.7%); and for patients with a history of transformed FL (45.9% v 4.7%), but not among patients without (8.1% v 6.2%). Overall, 77 of 140 deaths as a result of lymphoma occurred in patients whose FL transformed after diagnosis. CONCLUSION: Despite the improvement in overall survival in patients with FL in the rituximab era, their leading COD remains lymphoma, especially after disease transformation. Treatment-related mortality also represents a concern, which supports the need for less-toxic therapies.
Authors: Daryl Tan; Sandra J Horning; Richard T Hoppe; Ronald Levy; Saul A Rosenberg; Bronislava M Sigal; Roger A Warnke; Yasodha Natkunam; Summer S Han; Alan Yuen; Sylvia K Plevritis; Ranjana H Advani Journal: Blood Date: 2013-06-18 Impact factor: 22.113
Authors: Nina D Wagner-Johnston; Brian K Link; Michelle Byrtek; Keith L Dawson; John Hainsworth; Christopher R Flowers; Jonathan W Friedberg; Nancy L Bartlett Journal: Blood Date: 2015-06-23 Impact factor: 22.113
Authors: Kirit M Ardeshna; Wendi Qian; Paul Smith; Nivette Braganca; Lisa Lowry; Pip Patrick; June Warden; Lindsey Stevens; Christopher F E Pocock; Fiona Miall; David Cunningham; John Davies; Andrew Jack; Richard Stephens; Jan Walewski; Burhan Ferhanoglu; Ken Bradstock; David C Linch Journal: Lancet Oncol Date: 2014-03-04 Impact factor: 41.316
Authors: Carla Casulo; Michelle Byrtek; Keith L Dawson; Xiaolei Zhou; Charles M Farber; Christopher R Flowers; John D Hainsworth; Matthew J Maurer; James R Cerhan; Brian K Link; Andrew D Zelenetz; Jonathan W Friedberg Journal: J Clin Oncol Date: 2015-06-29 Impact factor: 44.544
Authors: Mazyar Shadman; Hongli Li; Lisa Rimsza; John P Leonard; Mark S Kaminski; Rita M Braziel; Catherine M Spier; Ajay K Gopal; David G Maloney; Bruce D Cheson; Shaker Dakhil; Michael LeBlanc; Sonali M Smith; Richard I Fisher; Jonathan W Friedberg; Oliver W Press Journal: J Clin Oncol Date: 2018-01-22 Impact factor: 44.544
Authors: Mariano Provencio; Ana Royuela; María Torrente; Marina Pollán; José Gómez-Codina; Pilar Sabín; Marta Llanos; Josep Gumá; Cristina Quero; Ana Blasco; David Aguiar; Francisco Ramón García-Arroyo; Javier Lavernia; Natividad Martínez; Manuel Morales; Álvaro Saenz-Cusi; Delvys Rodríguez; Virginia Calvo; Luis de la Cruz-Merino; Miguel Ángel de la Cruz; Antonio Rueda Journal: Cancer Date: 2017-06-13 Impact factor: 6.860
Authors: Lindsay M Morton; Rochelle E Curtis; Martha S Linet; Elizabeth C Bluhm; Margaret A Tucker; Neil Caporaso; Lynn A G Ries; Joseph F Fraumeni Journal: J Clin Oncol Date: 2010-10-12 Impact factor: 44.544
Authors: Lauren R Teras; Carol E DeSantis; James R Cerhan; Lindsay M Morton; Ahmedin Jemal; Christopher R Flowers Journal: CA Cancer J Clin Date: 2016-09-12 Impact factor: 508.702
Authors: Mariano Provencio; Pilar Sabín; Jose Gomez-Codina; Maria Torrente; Virginia Calvo; Marta Llanos; Josep Gumá; Cristina Quero; Ana Blasco; Miguel Angel Cruz; David Aguiar; Francisco García-Arroyo; Javier Lavernia; Natividad Martinez; Manuel Morales; Alvaro Saez-Cusi; Delvys Rodriguez; Luis de la Cruz; Jose Javier Sanchez; Antonio Rueda Journal: PLoS One Date: 2017-05-11 Impact factor: 3.240
Authors: Frédérique St-Pierre; Stephen M Broski; Betsy R LaPlant; Matthew J Maurer; Kay Ristow; Gita Thanarajasingam; William R Macon; Thomas M Habermann; Thomas E Witzig Journal: Oncologist Date: 2020-04-28
Authors: Pablo Mozas; Andrea Rivero; Alfredo Rivas-Delgado; Ferran Nadeu; Juan Gonzalo Correa; Carlos Castillo; Alex Bataller; Tycho Baumann; Eva Giné; Julio Delgado; Neus Villamor; Elías Campo; Laura Magnano; Armando López-Guillermo Journal: Ann Hematol Date: 2021-02-25 Impact factor: 3.673
Authors: Paolo Strati; Preetesh Jain; Ralph J Johnson; Sheryl Forbes; Lei Feng; Felipe Samaniego; Maria A Rodriguez; Luis E Fayad; Fredrick Hagemeister; Jason Westin; Michael Wang; Sattva S Neelapu; Loretta J Nastoupil; Nathan H Fowler Journal: Blood Date: 2021-02-25 Impact factor: 22.113
Authors: Thomas M Habermann; Arushi Khurana; Ruth Lentz; John J Schmitz; Alexander G von Bormann; Jason R Young; Christopher H Hunt; Sara N Christofferson; Grzegorz S Nowakowski; Kristen B McCullough; Pedro Horna; Adam J Wood; William R Macon; Paul J Kurtin; Scott C Lester; Scott L Stafford; Ushrasree Chamarthy; Faraz Khan; Stephen M Ansell; Rebecca L King Journal: Leuk Lymphoma Date: 2020-09-23